Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of cenegermin ophthalmic solution versus vehicle for persistent corneal epithelial defect
NL-OMON61105Phase 3Not yet recruiting
- Sponsor
- Dompé
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in corneal persistent epithelial defect (PED) comparing Cenegermin ophthalmic solution with Vehicle (2 arms). Primary endpoint: Complete epithelial healing at week 4 maintained at week 8. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cenegermin
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on NL-OMON61105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61105.